title: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
abstract: The 55-kilodalton (kDa) protein from the E1B-region of adenovirus binds to and inactivates the p53 gene, which is mutated in half of human cancers. We have previously shown that the replication and cytopathogenicity of an E1B, 55-kDa gene-attenuated adenovirus, ONYX-015, is blocked by functional p53 in RKO and U20S carcinoma lines. We now report that normal human cells were highly resistant to ONYX-015-mediated, replication-dependent cytolysis. In contrast, a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences (exons 5-9), were efficiently destroyed. Antitumoral efficacy was documented following intratumoral or intravenous administration of ONYX-015 to nude mouse-human tumor xenografts; efficacy with ONYX-015 plus chemotherapy (cisplatin, 5-fluorouracil) was significantly greater than with either agent alone.
authors.affiliation: ONYX Pharmaceuticals, Richmond, California 94806, USA.
authors.forename: C
authors.initials: C
authors.lastname: Heise
authors.forename: A
authors.initials: A
authors.lastname: Sampson-Johannes
authors.forename: A
authors.initials: A
authors.lastname: Williams
authors.forename: F
authors.initials: F
authors.lastname: McCormick
authors.forename: D D
authors.initials: DD
authors.lastname: Von Hoff
authors.forename: D H
authors.initials: DH
authors.lastname: Kirn
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D017501:Adenovirus E1B Proteins / Q000235:genetics*; D000956:Antigens, Viral / Q000378:metabolism; D002213:Capsid / Q000378:metabolism; D036022:Capsid Proteins; D002478:Cells, Cultured; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage; D004730:Endothelium, Vascular / Q000821:virology*; D004848:Epithelium / Q000821:virology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy; D006801:Humans; D015552:Injections, Intralesional; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000628:therapy; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000628:therapy*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000502:physiology; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy
chemical_list: D017501:Adenovirus E1B Proteins; D000956:Antigens, Viral; D036022:Capsid Proteins; D016159:Tumor Suppressor Protein p53; C018315:hexon capsid protein, Adenovirus; D002945:Cisplatin; D005472:Fluorouracil